Pre-clinical evidence certainly supports this strategy [38], although a recently published Phase II clinical trial in metastatic HNSCC patients using an IGF-1R monoclonal antibody as mono-therapy has proven to be disappointing [39]. The gene discussed is IGF1R; the disease is head and neck squamous cell carcinoma.